Figure 5.
Anti-tumor efficacy and body weight change in the KRAS G12D mutant PDAC xenograft model AsPC-1. Mice were treated with indicated KRAS G12D inhibitors and dose levels. A: antitumor efficacy; B: body weight change. Graphed data points represent group means (n = 8), and error bars represent SEM.